Equities analysts expect that Stealth BioTherapeutics Corp (NASDAQ:MITO) will post earnings per share of ($0.04) for the current quarter, according to Zacks. Zero analysts have made estimates for Stealth BioTherapeutics’ earnings. The business is expected to announce its next quarterly earnings results on Wednesday, November 13th.
According to Zacks, analysts expect that Stealth BioTherapeutics will report full year earnings of ($0.30) per share for the current financial year, with EPS estimates ranging from ($0.34) to ($0.25). For the next financial year, analysts expect that the firm will post earnings of ($0.20) per share, with EPS estimates ranging from ($0.26) to ($0.13). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Stealth BioTherapeutics.
Stealth BioTherapeutics (NASDAQ:MITO) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.04.
NASDAQ MITO traded down $0.13 during trading hours on Wednesday, hitting $6.29. 2,500 shares of the company traded hands, compared to its average volume of 21,823. The business’s 50-day moving average is $6.81 and its 200-day moving average is $11.13. Stealth BioTherapeutics has a twelve month low of $4.97 and a twelve month high of $20.99. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.13 and a current ratio of 2.13. The stock has a market capitalization of $231.20 million and a price-to-earnings ratio of -4.46.
Stealth BioTherapeutics Company Profile
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Further Reading: Is it better to buy a fund with a higher or lower NAV?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.